In the USA, children with sickle cell disease increasingly survive into adulthood, leading to an expanding population of ...

Risk for all-cause mortality and MACEs are affected by calcified and low-attenuation plaque burdens in patients with chronic kidney disease.

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...

A new study published in the journal of BMC Nephrology showed that the effectiveness of roxadustat is comparable at varying ...

Sotagliflozin, a dual SGLT1/2 inhibitor, increased hemoglobin levels in patients with type 2 diabetes and chronic kidney ...

AKI - the other main type of kidney disease - can be caused by dehydration, blood loss, urinary tract obstructions such as ...

The following is a summary of “Erythrocyte indices and response to hypoxia-inducible factor prolyl hydroxylase inhibitors in ...

While anemia impacts nearly a quarter of the world's population ... marked by an inability to utilize stored iron due to ...

Bengaluru, November 19, 2024 –Emcure Pharmaceuticals Ltd., a leading Indian pharmaceutical company, launched a nationwide public awareness campaign t ...

Patients with symptomatic anemia associated with chronic kidney disease who are on chronic maintenance dialysis can now also ...

Patients with symptomatic anaemia associated with chronic kidney disease who are on chronic maintenance dialysis can now also receive vadadustat ...

Patients with symptomatic anemia associated with chronic kidney disease who are on chronic maintenance dialysis can now also receive vadadustat instead of an erythropoiesis-stimulating agent such ...